BEYOND

CABENUVA was preferred by most survey participants

Patients in the real-world BEYOND study who reached Month 24 or discontinued were asked to respond to a survey question about which regimen they preferred.

These results are descriptive in nature and should not be used to infer clinical significance. Interpret results using limitations in study design.

Top three patient-reported reasons* for preferring CABENUVA

*Responses were pre-populated and respondents were permitted to choose more than one reason. Participant experience was evaluated using questionnaires.

SOLAR

PATIENT PREFERENCE

In the SOLAR Clinical Study, every-2-month CABENUVA was preferred by 9 out of 10 survey respondents vs daily oral therapy with BIKTARVY2,3

At Month 12 analysis or study withdrawal (secondary endpoint), all CABENUVA-treated patients in SOLAR (mITT-E; n=447) were asked to respond to a question about which regimen they preferred. 22 patients did not respond. Of the 425 respondents:

  • Why did patients prefer CABENUVA?

    The most commonly chosen responses were1*:

    Respondents could choose one or more reasons for their preference.

    *Patients who preferred CABENUVA were given a list of 11 reasons to choose from; more than one reason could be chosen.

Do you have established patients who may benefit from a long-acting regimen?

See Will’s story

mITT-E=modified intent-to-treat exposed.

References:

  1. Felizarta F, Alozie O, Miller R, et al. Perspectives of people with HIV-1 24 months following a switch to cabotegravir and rilpivirine long-acting (CAB + RPV LA) in an observational real-world US study (BEYOND). Poster presented at 13th IAS Conference on HIV Science, July 13-17, 2025, Kigali, Rwanda.
  2. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577.  doi.org/10.1016/S2352-3018(23)00136-4
  3. Data on file. ViiV Healthcare group of companies. Durham, NC.

PMUS-CBRWCNT250026